Finke D, Romann SW, Heckmann MB, et al. - High-sensitivity cardiac troponin T (hs-cTnT) measurement affords a crucial means to stratify mortality risk of cancer patients before initiating chemotherapy.

• A cohort study with 930 patients admitted to the cardio-oncology outpatient clinic.

• Most patients had breast cancer (n = 450, 48.4%), upper gastrointestinal carcinoma (n = 99, 10.6%) or multiple myeloma (n = 51, 5.5%).

• At the initial visit and second follow up, a preserved left ventricular ejection fraction (LVEF >50%) was detected in 86.7% and 78.9% of patients, respectively.

• hs-cTnT enabled detection of patients with high mortality by using a low cutoff of 7 ng/L, based on a non-selected cohort of cardio-oncological patients.